Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + chemotherapy + autologous NK cells for extensive-stage small cell lung cancer
ChiCTR2100046185Phase 2Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of tislelizumab and troculeucel in small cell lung cancer (SCLC) (3 arms), sponsored by First Hospital of China Medical University. Primary endpoints: 1-year progression-free survival rate, Safety evaluation and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
tislelizumabtroculeucel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2100046185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046185.